Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

ISRN Oncology
doi 10.1155/2014/931858
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Hindawi Limited

Related search

A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: The Combination of Idelalisib and Rituximab

Postdoc journal
2014English

Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab Into Clinical Practice

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Cost-Utility of Idelalisib in Combination With Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Chronic Lymphocytic Leukemia

Current Opinion in Hematology
Hematology
1998English

Chronic Lymphocytic Leukemia

Orvosi Hetilap
Medicine
2008English

Chronic Lymphocytic Leukemia

ASH Image Bank
2003English

Chronic Lymphocytic Leukemia

Molecular and Translational Medicine
2018English

Chronic Lymphocytic Leukemia

Hematology/Oncology Clinics of North America
OncologyHematology
2004English

VENETOCLAX IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (Literature Review)

Oncogematologiya
OncologyHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy